/

Empresas

Bi

No verificado

Biocytogen

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaIndustriaSalud

13 Comunicados de prensa

Ver todos los comunicados de prensa

07/07/2026

Multimedia

Oncología

Salud

Biotecnología

Ciencia

Farmacéutica

Mercado laboral

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Fuente

Editor

1.00

0

07/07/2026

Mercado laboral

Oncología

Salud

Biotecnología

Ciencia

Farmacéutica

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Fuente

Editor

1.00

0

15/06/2026

Industria

Veterinaria

Ciencia

Política Nacional

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

Fuente

Editor

1.00

0

15/06/2026

Industria

Veterinaria

Ciencia

Política Nacional

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

Fuente

Editor

1.00

0

26/05/2026

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure

Fuente

Editor

1.00

0

26/05/2026

Técnica

Ciencia

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Sanidad

Industria

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure

Fuente

Editor

1.00

0

28/02/2026

Industria

Salud

Sanidad

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

Fuente

Editor

1.00

0

09/01/2026

Mercado laboral

Industria

Oncología

Salud

Ciencia

Farmacéutica

Biotecnología

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)

Fuente

Editor

1.00

0

17/06/2025

Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing

Fuente

Editor

1.00

0

09/01/2025

Mercado laboral

Industria

Ciencia

Material médico sanitario

Biotecnología

Medicina - Varios

Farmacéutica

Salud

Oncología

Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0